AGENUS INC. Files 8-K on Financials

Ticker: AGEN · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1098972

Sentiment: neutral

Topics: financial-condition, results-of-operations, sec-filing

TL;DR

AGENUS INC. dropped an 8-K on March 11th about their financials. Check it out.

AI Summary

On March 11, 2025, AGENUS INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This 8-K filing indicates that AGENUS INC. is providing updates on its financial performance and condition to the SEC, which is important for investors to assess the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, with no immediate indication of significant negative events.

Key Players & Entities

FAQ

What specific financial results are being reported by AGENUS INC. in this 8-K?

The filing indicates it concerns 'Results of Operations and Financial Condition' but does not provide specific figures in the excerpt.

What is the primary purpose of this 8-K filing for AGENUS INC.?

The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on the company's results of operations and financial condition, and including financial statements and exhibits.

When was this 8-K report filed with the SEC?

The report was filed on March 11, 2025.

What is AGENUS INC.'s principal executive office address?

The principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts, 02421.

Has AGENUS INC. operated under any former names?

Yes, AGENUS INC. was formerly known as ANTIGENICS INC /DE/, with a name change date of November 15, 1999.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding AGENUS INC (AGEN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing